Neuraxis (NRXS) Cash & Equivalents (2022 - 2026)

Neuraxis has reported Cash & Equivalents for 5 years, with the latest figure at $7.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 252.99% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 252.99% YoY) and the FY2023 annual result came in at $78560.0, down 69.03% from the prior year.
• Cash & Equivalents climbed to $7.1 million in Q1 2026 per NRXS's latest filing, from $4.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $7.1 million in Q1 2026 and troughed at $51440.0 in Q2 2023.
• A 5-year average of $2.1 million and a median of $761249.0 in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 69.03% in 2023, then soared 3331.71% in 2024.
• Over 5 years, Cash & Equivalents stood at $253699.0 in 2022, then tumbled by 69.03% to $78560.0 in 2023, then soared by 232.08% to $260885.0 in 2024, then jumped by 1577.79% to $4.4 million in 2025, then surged by 61.72% to $7.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.1 million, $4.4 million, and $6.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.